246 related articles for article (PubMed ID: 17109305)
1. A trial of integrated buprenorphine/naloxone and HIV clinical care.
Sullivan LE; Barry D; Moore BA; Chawarski MC; Tetrault JM; Pantalon MV; O'Connor PG; Schottenfeld RS; Fiellin DA
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S184-90. PubMed ID: 17109305
[TBL] [Abstract][Full Text] [Related]
2. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients.
Tetrault JM; Moore BA; Barry DT; O'Connor PG; Schottenfeld R; Fiellin DA; Fiellin LE
J Subst Abuse Treat; 2012 Dec; 43(4):433-9. PubMed ID: 22938914
[TBL] [Abstract][Full Text] [Related]
3. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.
Korthuis PT; King C; Cook RR; Khuyen TT; Kunkel LE; Bart G; Nguyen T; Thuy DT; Bielavitz S; Nguyen DB; Tam NTM; Giang LM
Lancet HIV; 2021 Feb; 8(2):e67-e76. PubMed ID: 33539760
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
[TBL] [Abstract][Full Text] [Related]
5. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
Altice FL; Bruce RD; Lucas GM; Lum PJ; Korthuis PT; Flanigan TP; Cunningham CO; Sullivan LE; Vergara-Rodriguez P; Fiellin DA; Cajina A; Botsko M; Nandi V; Gourevitch MN; Finkelstein R;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S22-32. PubMed ID: 21317590
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
[TBL] [Abstract][Full Text] [Related]
7. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.
Rosenthal RN; Lofwall MR; Kim S; Chen M; Beebe KL; Vocci FJ;
JAMA; 2016 Jul; 316(3):282-90. PubMed ID: 27434441
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
[TBL] [Abstract][Full Text] [Related]
9. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
Fiellin DA; Pantalon MV; Chawarski MC; Moore BA; Sullivan LE; O'Connor PG; Schottenfeld RS
N Engl J Med; 2006 Jul; 355(4):365-74. PubMed ID: 16870915
[TBL] [Abstract][Full Text] [Related]
10. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.
Fiellin DA; Weiss L; Botsko M; Egan JE; Altice FL; Bazerman LB; Chaudhry A; Cunningham CO; Gourevitch MN; Lum PJ; Sullivan LE; Schottenfeld RS; O'Connor PG;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(0 1):S33-8. PubMed ID: 21317592
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
Webster L; Hjelmström P; Sumner M; Gunderson EW
J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
[TBL] [Abstract][Full Text] [Related]
13. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.
Woody GE; Poole SA; Subramaniam G; Dugosh K; Bogenschutz M; Abbott P; Patkar A; Publicker M; McCain K; Potter JS; Forman R; Vetter V; McNicholas L; Blaine J; Lynch KG; Fudala P
JAMA; 2008 Nov; 300(17):2003-11. PubMed ID: 18984887
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
Amato P
Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
[TBL] [Abstract][Full Text] [Related]
15. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial.
Lucas GM; Chaudhry A; Hsu J; Woodson T; Lau B; Olsen Y; Keruly JC; Fiellin DA; Finkelstein R; Barditch-Crovo P; Cook K; Moore RD
Ann Intern Med; 2010 Jun; 152(11):704-11. PubMed ID: 20513828
[TBL] [Abstract][Full Text] [Related]
16. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
[TBL] [Abstract][Full Text] [Related]
18. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone.
Sullivan LE; Botsko M; Cunningham CO; O'Connor PG; Hersh D; Mitty J; Lum PJ; Schottenfeld RS; Fiellin DA;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S54-61. PubMed ID: 21317595
[TBL] [Abstract][Full Text] [Related]
19. A pilot study about the feasibility and cost-effectiveness of electronic compliance monitoring in substitution treatment with buprenorphine-naloxone combination.
Tacke U; Uosukainen H; Kananen M; Kontra K; Pentikänen H
J Opioid Manag; 2009; 5(6):321-9. PubMed ID: 20073406
[TBL] [Abstract][Full Text] [Related]
20. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence.
Sullivan LE; Moore BA; O'Connor PG; Barry DT; Chawarski MC; Schottenfeld RS; Fiellin DA
Am J Addict; 2010; 19(1):53-8. PubMed ID: 20132122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
